Project/Area Number |
21249076
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Thoracic surgery
|
Research Institution | National Cardiovascular Center Research Institute |
Principal Investigator |
TATSUMI Eisuke 独立行政法人国立循環器病研究センター, 研究所, 部長 (00216996)
|
Co-Investigator(Kenkyū-buntansha) |
TAENAKA Yoshiyuki 国立循環器病研究センター, 研究所, 副所長 (00142183)
MASYUZAWA Toru 茨城大学, 工学部, 教授 (40199691)
|
Co-Investigator(Renkei-kenkyūsha) |
TAKEWA Yoshiaki 国立循環器病研究センター, 研究所, 室長 (20332405)
MIZUNO Toshihide 国立循環器病研究センター, 研究所, 室長 (40426515)
TSUKIYA Tomonori 国立循環器病研究センター, 研究所, 室長 (00311449)
HOMMA Akihijko 東京電機大学, 工学部, 教授 (20287428)
|
Project Period (FY) |
2009-05-11 – 2014-03-31
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥35,100,000 (Direct Cost: ¥27,000,000、Indirect Cost: ¥8,100,000)
Fiscal Year 2013: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Fiscal Year 2012: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2011: ¥9,230,000 (Direct Cost: ¥7,100,000、Indirect Cost: ¥2,130,000)
Fiscal Year 2010: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
|
Keywords | 小児重症心不全 / 機械的補助循環 / 抗血栓性 / 補助人工心臓 / 経皮的心肺補助 / VAD / ECMO / PCPS / 補助循環 / 機械的循環補助 |
Research Abstract |
We developed several types of next-generation pediatric circulatory support systems. The cardiopulmonary support system with long-term durability and superior antithrombotic property can provide safe long-term cardiopulmonary support, and is expected as ultimate therapeutic option for the possible pandemic of high mortality infectious diseases. We also proceeded research and development of three different types of artificial hearts: 1) NCVC type pneumatic paracorporeal pediatric ventricular assist device, 2) implantable axial flow ventricular assist device for infants, and 3) ultra-compact implantable axial flow pediatric ventricular assist device with hydrodynamic bearings. All systems have significantly progressed and came to: 1) pharmaceutical application within 1 year, 2) product design phase, and 3) preclicnical test phase, respectively. Our research and development activity will be continued and accelerated, aiming at earliest clinical application.
|